THE STRUCTURED CLINICAL INTERVIEW FOR COMPLICATED GRIEF: RELIABILITY, VALIDITY, AND EXPLORATORY FACTOR ANALYSIS

table 1 presents basic descriptive statistics

alpha=.78, good retest reliability interclass correlation ICC 0.68, 95% CI (0.60-0.75)
timebetweenassessments=17.6 days, SD=14.5, median=14, range=0-104

DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS

overview of established ocd animal model
glutamate directly preceding stereotypic behaviors 87 genetic model

COGNITION-CHILDHOOD MALTREATMENT INTERACTIONS IN THE PREDICTION OF ANTIDEPRESSANT OUTCOMES IN MAJOR DEPRESSIVE DISORDER PATIENTS: RESULTS FROM THE iSPOT-D TRIAL

composite capacity scores across 9 neurocognitive test
second level analysis involved unpaired t test

64*64 matrix; 24 cm FOV; TR=2500 ms; TE=27.5 ms flip angle=90
TR=8.3 ms; TE=3.2 ms flip angle=11°; TI=500 ms; NEX=1; ASSET=1.5
included HDRS17 response (50% improvement from baseline), HDRS17 remission posttreatment score<7
Wilks' lambda=0.814, F=2.050, df=9, p=0.044, partialeta squared=0.186
Wilks' lambda=0.857, F=1.447, df=9, p=0.183, partialeta squared=0.143
Wilks' lambda=0.837, F=1.685, df=9, p=0.107, partialeta squared=0.163
Wilks' lambda=0.930, F=0.657, df=9, p=0.745, partialeta squared=0.070

LONG-TERM OUTCOME OF MINDFULNESS-BASED COGNITIVE THERAPY IN RECURRENTLY DEPRESSED PATIENTS WITH AND WITHOUT A DEPRESSIVE EPISODE AT BASELINE

depressed subgroups bp values of chi square test

META-ANALYSIS OF ACUTE EXERCISE EFFECTS ON STATE ANXIETY: AN UPDATE OF RANDOMIZED CONTROLLED TRIALS OVER THE PAST 25 YEARS

AN OPEN TRIAL OF EMOTION REGULATION THERAPY FOR GENERALIZED ANXIETY DISORDER AND COOCCURRING DEPRESSION

regulation questionnaire; EQ=experiences questionnaire; AIM=affective intensity scale; aP<.05; ∗∗P<.01;∗∗∗ p<.001

THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS

manufacturer's maximum 9% prescribe>450 mg/day 27% prescribe>60 mg/day 53% prescribe>40 mg/day 29% prescribe>100 mg/day 70% prescribe>20 mg/day 55% prescribe>1800 mg/day 16% prescribe>400 mg/day 12% prescribe>60 mg/day 40% prescribe>200 mg/day 83% prescribe>225